

COMPANY OVERVIEW

We are a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative, “orphan”, diseases with high unmet medical need. Our internal drug discovery programs are focused on therapeutic applications of monoclonal antibodies and antibody-drug conjugates.

We have a strong track record of executing successful license agreements with leading pharmaceutical companies. As an example, we licensed a naturally derived, small molecule, potent antioxidant to Shire Plc (“Shire”), which recently tested the drug candidate in patients with Friedreich’s Ataxia, a rare, hereditary disorder that leads to progressive and irreversible damage to the nervous system. We are entitled to substantial future payments upon achievement of certain milestones by Shire and significant royalties from sales upon approval of the drug by the US FDA and corresponding foreign regulatory agencies. Friedreich’s Ataxia affects an estimated 1 in 30,000 to 50,000 people in the United States and a similar number in ex-US countries.

Our global patent estate, which includes 85 issued patents spanning composition of matter and methods of use of various compounds for the treatment of neurodegenerative diseases (e.g. tauopathies and proteinopathies), protects our proprietary interest in novel antioxidants, amyloid beta monoclonal antibodies, tau monoclonal antibodies, antibody-drug conjugates (ADC) and related platform technologies.

RECENT NEWS

Intellect Neurosciences, Inc. Engages Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor for CONJUMAB-A Antibody Drug Conjugate Program

Mar 30 2016, 10:29 AM EDT

INVESTOR RELATIONS

MDM Worldwide
David Zazoff
T: 212-643-0417
ir@intellectns.com

MANAGEMENT TEAM

Elliot M. Maza, J.D., CPA

Chief Executive Officer and CFO; Chairman of the Board of Directors

INTELLECT NEUROSCIENCES, INC.

550 Sylvan Ave.
Englewood Cliffs, NJ 07632
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

